Literature DB >> 1683212

Alterations of dopaminergic and noradrenergic innervations in motor cortex in Parkinson's disease.

P Gaspar1, C Duyckaerts, C Alvarez, F Javoy-Agid, B Berger.   

Abstract

The motor areas of the cerebral cortex contain dense dopaminergic and noradrenergic innervation in humans. We looked for changes of these innervations in cases with Parkinson's disease (PD). The density of fibers immunolabeled with tyrosine hydroxylase or dopamine-beta-hydroxylase was evaluated in the primary motor, premotor, and prefrontal cortical regions in 6 cases with PD and 7 control cases. Reductions of both noradrenergic and dopaminergic cortical innervations were observed, with similar magnitudes of reduction found in the motor and prefrontal regions of the cortex. Depletion of noradrenergic innervation was diffuse, involving all cortical laminae. Depletion of dopaminergic innervation was laminar specific, with the most significant reductions in layers I and II; reductions in layers V and VI were either less marked (prefrontal cortex) or not detectable (primary motor). The results suggest the existence of two separate mesocortical dopaminergic systems in humans, with the one distributing to upper cortical layers being preferentially involved in PD.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1683212     DOI: 10.1002/ana.410300308

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  56 in total

1.  Effects of cortical and striatal dopamine D1 receptor blockade on cued versus noncued behavioral responses.

Authors:  Won Yung Choi; Cecile Morvan Campbell; Peter D Balsam; Jon C Horvitz
Journal:  Behav Neurosci       Date:  2011-10       Impact factor: 1.912

2.  Cortical glutamate levels decrease in a non-human primate model of dopamine deficiency.

Authors:  Z Zhang; J E Quintero; X T Fan; F Zhao; Y Ai; A Andersen; P Hardy; F Ling; G A Gerhardt
Journal:  Brain Res       Date:  2014-01-04       Impact factor: 3.252

3.  Amphetamine stimulates movement through thalamocortical glutamate release.

Authors:  Omar S Mabrouk; Daniel Z Semaan; Sarah Mikelman; Margaret E Gnegy; Robert T Kennedy
Journal:  J Neurochem       Date:  2013-08-19       Impact factor: 5.372

4.  Severe serotonin depletion after conditional deletion of the vesicular monoamine transporter 2 gene in serotonin neurons: neural and behavioral consequences.

Authors:  Nicolas Narboux-Nême; Corinne Sagné; Stephane Doly; Silvina L Diaz; Cédric B P Martin; Gaelle Angenard; Marie-Pascale Martres; Bruno Giros; Michel Hamon; Laurence Lanfumey; Patricia Gaspar; Raymond Mongeau
Journal:  Neuropsychopharmacology       Date:  2011-08-03       Impact factor: 7.853

5.  Effects of subthalamic nucleus stimulation on motor cortex plasticity in Parkinson disease.

Authors:  Sang Jin Kim; Kaviraja Udupa; Zhen Ni; Elena Moro; Carolyn Gunraj; Filomena Mazzella; Andres M Lozano; Mojgan Hodaie; Anthony E Lang; Robert Chen
Journal:  Neurology       Date:  2015-07-08       Impact factor: 9.910

Review 6.  Critical involvement of the motor cortex in the pathophysiology and treatment of Parkinson's disease.

Authors:  David Lindenbach; Christopher Bishop
Journal:  Neurosci Biobehav Rev       Date:  2013-10-07       Impact factor: 8.989

Review 7.  Motor learning in animal models of Parkinson's disease: Aberrant synaptic plasticity in the motor cortex.

Authors:  Tonghui Xu; Shaofang Wang; Rupa R Lalchandani; Jun B Ding
Journal:  Mov Disord       Date:  2017-03-25       Impact factor: 10.338

Review 8.  Chronic MPTP administration regimen in monkeys: a model of dopaminergic and non-dopaminergic cell loss in Parkinson's disease.

Authors:  Gunasingh J Masilamoni; Yoland Smith
Journal:  J Neural Transm (Vienna)       Date:  2017-08-31       Impact factor: 3.575

9.  Clinical Potential of Catechol-OMethyltransferase (COMT) Inhibitors as Adjuvants in Parkinson's Disease.

Authors:  P T Ménnistó
Journal:  CNS Drugs       Date:  1994-03       Impact factor: 5.749

10.  The alpha 2-adrenoceptor antagonist atipamezole potentiates anti-Parkinsonian effects and can reduce the adverse cardiovascular effects of dopaminergic drugs in rats.

Authors:  Antti Haapalinna; Tiina Leino; Esa Heinonen
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-10-18       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.